Danielle Boedeker, | |
285 Beiser Blvd Ste 202, Dover, DE 19904-7804 | |
(302) 747-5995 | |
Not Available |
Full Name | Danielle Boedeker |
---|---|
Gender | Female |
Speciality | Physical Therapy |
Experience | 4 Years |
Location | 285 Beiser Blvd Ste 202, Dover, Delaware |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1194310706 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
225100000X | Physical Therapist | (* (Not Available)) | Primary |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Thrive Physical Therapy | 9638410061 | 5 |
News Archive
Epsilon, an Alliance Data company, has signed multi-year renewal and expansion agreements with The Leukemia & Lymphoma Society the world's largest voluntary health agency dedicated to finding cures for blood cancers. Epsilon has partnered with the LLS since the early 1990s, providing marketing services geared toward engaging LLS constituents across a range of fundraising and donor programs such as Light the Night, Team In Training and Man & Women of the Year.
Genzyme Corp. and Isis Pharmaceuticals Inc. today announced that the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) met its primary endpoint with a highly statistically significant 28 percent reduction in LDL-cholesterol after 26 weeks of treatment, compared with an increase of 5 percent for placebo.
Vaccinex, Inc. has announced the award of a key European patent (European Patent No. 1340088) for its antibody discovery technology platform, branded as ActivMab Technology.
Understanding how any disease progresses is one of the first and most important steps towards finding treatments to stop it. This has been the case for such brain-degenerating conditions as Alzheimer's disease. Now, after several years of incremental study, researchers at the Perelman School of Medicine, University of Pennsylvania have been able to piece together important steps in how Parkinson's disease (PD) spreads from cell to cell and leads to nerve cell death.
In an effort to combat a growing worldwide epidemic of Nonalcoholic Fatty Liver Disease (NAFLD), scientists have discovered a new target and a new therapy that has shown promising results in preclinical mouse models, according to researchers at the University of Colorado Anschutz Medical Campus.
› Verified 6 days ago
Provider Name | Ati Holdings Llc |
---|---|
Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
Provider Identifiers | NPI Number: 1396781050 PECOS PAC ID: 9537112719 Enrollment ID: O20061101000380 |
News Archive
Epsilon, an Alliance Data company, has signed multi-year renewal and expansion agreements with The Leukemia & Lymphoma Society the world's largest voluntary health agency dedicated to finding cures for blood cancers. Epsilon has partnered with the LLS since the early 1990s, providing marketing services geared toward engaging LLS constituents across a range of fundraising and donor programs such as Light the Night, Team In Training and Man & Women of the Year.
Genzyme Corp. and Isis Pharmaceuticals Inc. today announced that the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) met its primary endpoint with a highly statistically significant 28 percent reduction in LDL-cholesterol after 26 weeks of treatment, compared with an increase of 5 percent for placebo.
Vaccinex, Inc. has announced the award of a key European patent (European Patent No. 1340088) for its antibody discovery technology platform, branded as ActivMab Technology.
Understanding how any disease progresses is one of the first and most important steps towards finding treatments to stop it. This has been the case for such brain-degenerating conditions as Alzheimer's disease. Now, after several years of incremental study, researchers at the Perelman School of Medicine, University of Pennsylvania have been able to piece together important steps in how Parkinson's disease (PD) spreads from cell to cell and leads to nerve cell death.
In an effort to combat a growing worldwide epidemic of Nonalcoholic Fatty Liver Disease (NAFLD), scientists have discovered a new target and a new therapy that has shown promising results in preclinical mouse models, according to researchers at the University of Colorado Anschutz Medical Campus.
› Verified 6 days ago
Provider Name | Thrive Physical Therapy |
---|---|
Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
Provider Identifiers | NPI Number: 1225514268 PECOS PAC ID: 9638410061 Enrollment ID: O20190411000780 |
News Archive
Epsilon, an Alliance Data company, has signed multi-year renewal and expansion agreements with The Leukemia & Lymphoma Society the world's largest voluntary health agency dedicated to finding cures for blood cancers. Epsilon has partnered with the LLS since the early 1990s, providing marketing services geared toward engaging LLS constituents across a range of fundraising and donor programs such as Light the Night, Team In Training and Man & Women of the Year.
Genzyme Corp. and Isis Pharmaceuticals Inc. today announced that the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) met its primary endpoint with a highly statistically significant 28 percent reduction in LDL-cholesterol after 26 weeks of treatment, compared with an increase of 5 percent for placebo.
Vaccinex, Inc. has announced the award of a key European patent (European Patent No. 1340088) for its antibody discovery technology platform, branded as ActivMab Technology.
Understanding how any disease progresses is one of the first and most important steps towards finding treatments to stop it. This has been the case for such brain-degenerating conditions as Alzheimer's disease. Now, after several years of incremental study, researchers at the Perelman School of Medicine, University of Pennsylvania have been able to piece together important steps in how Parkinson's disease (PD) spreads from cell to cell and leads to nerve cell death.
In an effort to combat a growing worldwide epidemic of Nonalcoholic Fatty Liver Disease (NAFLD), scientists have discovered a new target and a new therapy that has shown promising results in preclinical mouse models, according to researchers at the University of Colorado Anschutz Medical Campus.
› Verified 6 days ago
Mailing Address | Practice Location Address |
---|---|
Danielle Boedeker, 790 Remington Blvd, Bolingbrook, IL 60440-4909 Ph: () - | Danielle Boedeker, 285 Beiser Blvd Ste 202, Dover, DE 19904-7804 Ph: (302) 747-5995 |
News Archive
Epsilon, an Alliance Data company, has signed multi-year renewal and expansion agreements with The Leukemia & Lymphoma Society the world's largest voluntary health agency dedicated to finding cures for blood cancers. Epsilon has partnered with the LLS since the early 1990s, providing marketing services geared toward engaging LLS constituents across a range of fundraising and donor programs such as Light the Night, Team In Training and Man & Women of the Year.
Genzyme Corp. and Isis Pharmaceuticals Inc. today announced that the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) met its primary endpoint with a highly statistically significant 28 percent reduction in LDL-cholesterol after 26 weeks of treatment, compared with an increase of 5 percent for placebo.
Vaccinex, Inc. has announced the award of a key European patent (European Patent No. 1340088) for its antibody discovery technology platform, branded as ActivMab Technology.
Understanding how any disease progresses is one of the first and most important steps towards finding treatments to stop it. This has been the case for such brain-degenerating conditions as Alzheimer's disease. Now, after several years of incremental study, researchers at the Perelman School of Medicine, University of Pennsylvania have been able to piece together important steps in how Parkinson's disease (PD) spreads from cell to cell and leads to nerve cell death.
In an effort to combat a growing worldwide epidemic of Nonalcoholic Fatty Liver Disease (NAFLD), scientists have discovered a new target and a new therapy that has shown promising results in preclinical mouse models, according to researchers at the University of Colorado Anschutz Medical Campus.
› Verified 6 days ago
Adrianne Greene, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1288 S Governors Ave, Dover, DE 19904 Phone: 302-677-0100 Fax: 302-677-0267 | |
Ms. Amy Kathryn Tullis, PT, MPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 97 Commerce Way, Suite 101, Dover, DE 19904 Phone: 302-734-8000 | |
Jihwan Jeong, Physical Therapist Medicare: Medicare Enrolled Practice Location: 1288 S Governors Ave, Dover, DE 19904 Phone: 302-677-0100 | |
Matthew Vassalotti, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1288 S Governors Ave, Dover, DE 19904 Phone: 302-677-0100 Fax: 302-677-0267 | |
Kathy Tompkins, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 945 Forest St, Dover, DE 19904 Phone: 302-672-1500 | |
Christine Marie Reynolds, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1203 Walker Rd, Dover, DE 19904 Phone: 302-735-8800 | |
Katherine Marie Monahan, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1288 S Governors Ave, Dover, DE 19904 Phone: 302-677-0100 |